Anthelmintics nitazoxanide protects against experimental hyperlipidemia and hepatic steatosis in hamsters and mice
Lipid metabolism disorders contribute to hyperlipidemia and hepatic steatosis. It is ideal to develop drugs simultaneous improving both hyperlipidemia and hepatic steatosis. Nitazoxanide is an FDA-approved oral antiprotozoal drug with excellent pharmacokinetic and safety profile. We found that nitaz...
Saved in:
Main Authors: | Fengfeng Li (Author), Man Jiang (Author), Minghui Ma (Author), Xuyang Chen (Author), Yidan Zhang (Author), Yixin Zhang (Author), Yuanyuan Yu (Author), Yunfeng Cui (Author), Jiahui Chen (Author), Hui Zhao (Author), Zhijie Sun (Author), Deli Dong (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The clinical antiprotozoal drug nitazoxanide and its metabolite tizoxanide extend Caenorhabditis elegans lifespan and healthspan
by: Wenfeng Li, et al.
Published: (2024) -
Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways
by: Kent Miner, et al.
Published: (2019) -
Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters
by: Lulu Sun, et al.
Published: (2019) -
Structural Characterization of Peptides From Huangjiu and Their Regulation of Hepatic Steatosis and Gut Microbiota Dysbiosis in Hyperlipidemia Mice
by: Ying Shi, et al.
Published: (2021) -
Cordycepin Prevents Hyperlipidemia in Hamsters Fed a High-Fat Diet via Activation of AMP-Activated Protein Kinase
by: Peng Guo, et al.
Published: (2010)